Abbvie Inc. vs Protagonist Therapeutics, Inc
ABBV vs PTGX — side-by-side comparison from reported financials. ABBV leads 6, PTGX leads 4 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Protagonist Therapeutics, Inc
PTGX · Healthcare
$143.00+2.21%Strong
| Metric | ABBV | PTGX |
|---|---|---|
| Price | $276.43 | $143.00 |
| Market cap | $488B | $9.25B |
| Revenue (TTM) | $64.4B | $275M |
| Revenue growth | +1.8% | +20.1% |
| Net margin | 9.8% | 30.2% |
| Free cash flow | $18.2B | $131M |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | +113.3% |
| P/E | 77.4 | 112.2 |
| P/E vs own history (cheap-side %) | 23% | 21% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 12% |
| Altman Z-score | 2.33 | 139.54 |
| CV checks passed | 9 of 11 | 6 of 11 |
| Employees | 57,000 | 141 |
Full résumé-style profiles: ABBV CV · PTGX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.